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ABSTRACT. Duchenne muscular dystrophy (DMD) is a human disease 
characterized by progressive and irreversible skeletal muscle degeneration 
caused by mutations in genes coding for important muscle proteins. Un-
fortunately, there is no efficient treatment for this disease; it causes pro-
gressive loss of motor and muscular ability until death. The canine model 
(golden retriever muscular dystrophy) is similar to DMD, showing similar 
clinical signs.  Fifteen dogs were followed from birth and closely observed 
for clinical signs. Dogs had their disease status confirmed by polymerase 
chain reaction analysis and genotyping. Clinical observations of muscu-
loskeletal, morphological, gastrointestinal, respiratory, cardiovascular, and 390
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renal features allowed us to identify three distinguishable phenotypes in 
dystrophic dogs: mild (grade I), moderate (grade II) and severe (grade III). 
These three groups showed no difference in dystrophic alterations of mus-
cle morphology and creatine kinase levels. This information will be use-
ful for therapeutic trials, because DMD also shows significant, inter- and 
intra-familiar clinical variability. Additionally, being aware of phenotypic 
differences in this animal model is essential for correct interpretation and 
understanding of results obtained in pre-clinical trials.
Key words: Duchenne muscular dystrophy; Animal disease; Model; 
Phenotype
INTRODUCTION
Progressive muscular dystrophy is a group of diseases characterized by progressive and 
irreversible degeneration of skeletal muscles (Zatz, 2004). One of these diseases is Duchenne 
muscular dystrophy (DMD), which is a severe X-linked recessive disorder that shows high mor-
bidity and mortality. 
The incidence of DMD is one in 3000 male births (Nichols and Lymn, 1994; Passos-
Bueno and Zatz, 1995), and symptoms appear in the first years of life (3 to 5 years old). At ten 
years, patients show difficulties in locomotion; at 12 years they become wheelchair-bound, 
and between 20 and 30 years of age they die (Nichols and Lymn, 1994; Passos-Bueno and 
Zatz, 1995; Manzur and Muntoni, 2002). 
Many treatments have been attempted in the last 20 years, but they all have failed 
(Hoffman and Dressman, 2001; Dell’Agnola et al., 2004; Liu et al., 2004). New therapies are 
still under investigation, some of which are based on animal models (Dell’Agnola et al., 2004; 
McClorey et al., 2006; Kerkis et al., 2008). 
Currently, there are two animal models for DMD, namely the mdx mouse model, 
which is the one most used (Brazeau et al., 1992), and the GRMD (golden retriever mus-
cular dystrophy) canine model (Valentine et al., 1988). The latter is a promising model 
because besides showing the same clinical signs that have already been characterized 
in humans (Kornegay et al., 1988; Valentine et al., 1990; Valentine and Cooper, 1991; 
Nichols and Lymn, 1994; Bergman et al., 2002; Nguyen et al., 2002; Shelton and Engvall, 
2002; Collins and Morgan, 2003), these dogs carry the same frameshift mutation that is 
also seen in some DMD patients (Sharp et al., 1992). Other vertebrate models related to 
dystrophy have been well described by Vainzof et al. (2008). 
MATERIAL AND METHODS
In 2002, our group established the first and still the only GRMD kennel in Latin 
America (Ambrosio et al., 2008). Since then, we have been studying and characterizing this 
group of animals, hoping to better understand the disease in humans and to develop new ap-
proaches for treating muscular dystrophy. 
Herein, we summarize our findings on important clinical signs and pathological fea-
tures of 15 GRMD dogs after following these animals very closely from birth. Our observa-391
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tions allowed us to identify three different phenotypes, and to classify them as mild, moder-
ate and severe. All 15 GRMD dogs had their affected status confirmed by polymerase chain 
reaction analysis and genotyping (Figure 1A), according to a protocol described elsewhere 
(Honeyman et al., 1999; Kerkis et al., 2008). 
Figure 1. A. Duchenne muscular dystrophy genotyping of golden retriever muscular dystrophy (GRMD) puppies with 
X-linked muscular dystrophy that were genotyped within 48 h after birth. The genomic polymerase chain reaction 
product digested with Sau96I produces the wild-type band (310 bp) and the mutant band (150 bp) labeled with arrows. 
Squares = affected male. Filled circles = affected female. Open circles = carrier female. B. Grade I phenotype (Suflair 
dog). C. Grade II phenotype. D. Grade III phenotype showing general hypotrophy. Inset in B-D = thigh muscle mass. 
Histological parameters 
Muscle fragments were collected from the vastus lateralis muscle from each of the 15 
dogs. To avoid any motor loss of function in the GRMD animals, a single muscle was chosen 
to represent the pelvic limb. The hind limb is considered to be more affected in the canine 
dystrophy model (Howell et al., 1997), and the vastus lateralis was described by Childers et 
al. (2002) as a muscle group that incurs damage and regeneration between 1 and 6 months of 
age in GRMD dogs. 
An open biopsy was performed and a 0.5-cm2 fragment was collected from the middle 
portion of the muscle. After venous cannulation and fluid therapy, the dogs were subjected to 
an anesthetic protocol (Kerkis et al., 2008).392
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Fragments of muscle were cooled with liquid nitrogen and frozen at -80°C. Cross-
sections of 6 to 8 µm were made on a Leica Cryostat CM 1850 at -20°C and afterward stained 
with hematoxylin-eosin.
Creatine kinase analysis 
Blood samples were collected monthly by jugular venipuncture from the GRMD dogs. 
Serum creatine kinase was determined with an automated analyzer (Labtest® - LABTEST Di-
agnóstica S.A., Lagoa Santa, MG, Brazil). 
RESULTS
Clinical observations of the entire group of GRMD dogs showed that from birth af-
fected dogs are weaker and more lethargic than either non-affected or carrier dogs. Additionally, 
affected dogs showed lower daily weight gain and a high risk of developing hypoglycemia, hy-
pothermia and sepsis. Feeding when they are young is difficult because of tongue macroscopic 
hypertrophy, which results in difficulties in sucking (McKerrell, 2001). Supplementation with a 
replacement milk product for puppies (Royal Canin first age milk®, Aimargues, France) is done 
through an orogastric tube. After the initial most critical 15-day postnatal period, animals dem-
onstrated improved sucking and weight gain, showing the first critical period of life. 
In general, gastrointestinal alterations are noticed early, which progress in some dogs. 
In our dogs, dysphagia and excessive salivation were observed when dry food was ingested, 
which prompted us to replace the dry food with moist food when the animals were seven 
months old. However, they still presented megaesophagus, which resulted in regurgitation and 
esophagitis. These dogs also showed a sliding hiatal hernia, which led to emesis as the hernia-
tion enlarged. These alterations facilitated the occurrence of aspiration pneumonia in 60% of 
the affected dogs in the kennel. Tongue hypertrophy also makes water consumption difficult, 
which may result in dehydration, and requires the use of fluid therapy in some cases.
The first signs of muscular dystrophy were clearly noticed around the fourth month, 
when affected dogs showed tarsal overflexion with genu varum and genu valgum (cow’s hock) 
in the hind limbs. At this age, the dogs became thinner and displayed stifle hypomobility while 
walking. The fore limbs showed lateral rotations of the phalanges, resulting in carpal overflex-
ion with genu varum. Walking or exercise proved to be difficult skills after 6 months of age. 
As time passed, the limbs became stiff with range of joint motion absent or decreased while 
moving. Steps became short, with some dogs showing bunny hopping. At around two years of 
age, dogs can show dilated cardiomyopathy (Pellegrino et al., 2007). 
These clinical-pathological findings were observed in most of the GRMD dogs, either 
by our group or by others (Howell et al., 1997; McKerrell, 2001). However, a close observa-
tion of these 15 affected dogs allowed us to classify the phenotypes of these animals into three 
groups: mild, moderate and severe. The mild phenotype, termed grade I (Figure 1B), included 
five dogs, which showed less muscular and skeletal symmetry complications, such as less car-
pal overflexion with genu varum and minimal alterations in hind limbs (inset, Figure 1B), 
compared to the other dogs. Gastrointestinal alterations were of low grade, such as a discreet 
esophagus dilatation. Feeding was better than in other GRMD dogs, and these dogs showed no 
daily episodes of regurgitation (Grando et al., 2009). Cardiac problems and dehydration were 393
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not observed in this group of dogs. Animals in this group tolerated exercise better than others. 
Pathological muscle histology showed typical features of a dystrophic process with 
variability in fiber size, splitting, degeneration, endomysial fibrosis, fiber regeneration, and 
necrosis (Figure 2). This degeneration process was observed in all three groups, irrespective of 
phenotype. Creatine kinase levels were similarly high and variable in all three groups (Figure 
2) (Ambrosio et al., 2008; Kerkis et al., 2008). 
Figure 2. Description of clinical-pathological signs in three different golden retriever muscular dystrophy dog 
phenotypes. CK = creatine kinase.394
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The moderate phenotype, termed grade II (Figure 1C), included five dogs, which 
showed more severe clinical signs than those in the grade I group. Animals in this group 
also showed all the signs described earlier for the grade I group, but with alterations in 
hind limbs, such as tarsal overflexion with genu varum and genu valgum (cow’s hock), 
which resulted in bunny hopping. In this group, regurgitation was more frequent with 
dogs displaying two to ten episodes per day, which contributed to dehydration. Sliding 
hiatal hernia was observed by radiographic examination and showed sliding from 10 to 
15% into thoracic cavity (Alves et al., 2009). 
Grade III group showed carpal overflexion and genu varum, stifle hypomobility, 
tarsal overflexion with genu varum and genu valgum, which is associated with important 
hypotrophies such as musculoskeletal alterations. The gastrointestinal system showed 
tongue hypertrophy and megaesophagus. More than ten episodes per day of regurgitation 
were observed. They showed 30 to 40% sliding hiatal hernia, which was characterized by 
cardia, fundus and body herniation into the thoracic cavity (Figure 1D).
DISCUSSION
The identification and classification of these three phenotypes may reflect im-
portant inter- and intra-familiar clinical variability, which is seen in DMD patients and 
which cannot be attributed to genetic factors (Vainzof and Zatz, 2003), but a correlation 
between the amount of dystrophin and the severity of the phenotype has been suggested 
by the cited authors. Sifringer et al. (2004) suggested that an increase in some proteins 
such as casein kinase I, dynactin 3 light chain and the core-binding factor beta, which are 
involved in the regulation of the cell cycle, may be related to a milder phenotype. Future 
studies should be carried out to establish if a difference in the levels of dystrophin can also 
be observed in these dogs and whether these levels may explain the different phenotypes 
described here.
DMD has a milder variant known as Becker muscular dystrophy (BMD). BMD is 
less severe but displays variable phenotypes, ranging from a slightly less severe DMD-
like condition to a very mild condition. Some patients may be able to walk throughout 
their lives. A patient is classified as having DMD when wheelchair-dependent before the 
age of 13, and as having BMD when able to walk beyond the age of 16 (Vainzof and Zatz, 
2003). However, a recent clinical casebook described a boy without any signs of DMD 
(Dubowitz, 2006) but with confirmation of molecular findings. Both forms of muscular 
dystrophy are found in patients carrying similar mutations, which indicates that the phe-
notype cannot be determined solely by the genomic mutation in the Xp21 locus; other 
factors may also play a role. 
A similar situation is observed in GRMD dogs (Ambrosio et al., 2008). We pro-
pose the hypothesis that the milder phenotype described here is due to a modifier gene 
most likely inherited through male-to-male transmission. It is important to note that in 
our kennel we also have a number of affected female dogs that carry the same mutation in 
both X chromosomes; however, no variation in phenotype is seen among affected females. 
Therefore, it seems that the variation we observed among these affected dogs is somehow 
limited to males. Understanding the mechanism and genetic bases underlying these varia-
tions is of great interest (Ambrosio et al., 2007).395
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CONCLUSIONS
In summary, we identified three phenotypes of the GRMD dog, which is a promis-
ing animal model for DMD because these dogs show most of the signs found in the human 
disease, except the respiratory symptoms and loss of gait. However, the use of GRMD dogs 
in pre-clinical trials must be carried out carefully as the existence of different phenotypes may 
account for different responses to drugs and treatments. Therefore, the clinical outcome of 
therapeutic trials with GRMD dogs should be interpreted with caution. 
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